1h Free Analyst Time
The Glycated Albumin Assay Market size was estimated at USD 217.29 million in 2023, USD 232.69 million in 2024, and is expected to grow at a CAGR of 7.51% to reach USD 360.92 million by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Glycated albumin is a biomarker used for assessing and monitoring diabetes mellitus, reflecting shorter-term changes in blood glucose levels compared to other biomarkers such as glycated hemoglobin (HbA1c). The rising prevalence of diabetes and increasing public awareness about monitoring and controlling blood glucose raises need for accurate and reliable testing methods. However, reimbursement policies and regulatory frameworks in various countries may hinder the widespread use of glycated albumin assays. Nevertheless, expanding healthcare infrastructure in emerging economies provides greater access to advanced diagnostics tools such as glycated albumin assays, and research into novel biomarkers for glucose regulation is expected to create new avenues for growth within the glycated albumin assay market.
Regional Insights
The Americas has a significant landscape in the glycated albumin assay market owing to a substantial need for glycated albumin assay due to the high prevalence of diabetes in these countries. Additionally, countries have advanced healthcare systems that can support the adoption of innovative diagnostic tools such as glycated albumin assays. The growing aging population in Europe contributes significantly to the increasing demand for advanced diagnostics such as glycated albumin assays. EU countries have comprehensive healthcare systems that prioritize early detection of diseases such as diabetes, increasing the glycated albumin assay demand in the region. In the Middle East and Africa region, there has been a steady rise in lifestyle-related diseases, including diabetes, due to changing demographics and urbanization. Various programs, initiatives, and investments by legal authorities promoted the adoption of innovative diagnostic techniques in the region. The Asia Pacific market for glycated albumin assay is expanding rapidly due to the growing prevalence of diabetes, increasing research and development activities, and significant advancements in developing novel techniques for glycated albumin detection.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Glycated Albumin Assay Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Glycated Albumin Assay Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the Glycated Albumin Assay Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Abnova Corporation, Asahi Kasei Corporation, Beijing Strong Biotechnologies Inc., Cardinal Health Inc., Crystal Chem Inc., Diazyme Laboratories Inc., DxGen Corp., EKF Diagnostics Holdings PLC, Epinex Diagnostics Inc., Ethos Biosciences, Inc., FroggaBio Inc., Hymes Biotech, Laboratory Corporation of America Holdings, LifeSpan BioSciences, Inc., and Weldon Biotech Inc.Market Segmentation & Coverage
This research report categorizes the Glycated Albumin Assay Market to forecast the revenues and analyze trends in each of the following sub-markets:- Product
- Animal Glycated Albumin Assay
- Human Glycated Albumin Assay
- Application
- Prediabetes
- Type 1 Diabetes
- Type 2 Diabetes
- End User
- Diabetic Care Centres
- Diagnostic Laboratories
- Hospitals & Clinics
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Glycated Albumin Assay Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Glycated Albumin Assay Market?
- What are the technology trends and regulatory frameworks in the Glycated Albumin Assay Market?
- What is the market share of the leading vendors in the Glycated Albumin Assay Market?
- Which modes and strategic moves are suitable for entering the Glycated Albumin Assay Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Glycated Albumin Assay Market, by Product
7. Glycated Albumin Assay Market, by Application
8. Glycated Albumin Assay Market, by End User
9. Americas Glycated Albumin Assay Market
10. Asia-Pacific Glycated Albumin Assay Market
11. Europe, Middle East & Africa Glycated Albumin Assay Market
12. Competitive Landscape
13. Competitive Portfolio
14. Appendix
List of Figures
List of Tables
Companies Mentioned
- Abcam PLC
- Abnova Corporation
- Asahi Kasei Corporation
- Beijing Strong Biotechnologies Inc.
- Cardinal Health Inc.
- Crystal Chem Inc.
- Diazyme Laboratories Inc.
- DxGen Corp.
- EKF Diagnostics Holdings PLC
- Epinex Diagnostics Inc.
- Ethos Biosciences, Inc.
- FroggaBio Inc.
- Hymes Biotech
- Laboratory Corporation of America Holdings
- LifeSpan BioSciences, Inc.
- Weldon Biotech Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 191 |
| Published | March 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 232.69 Million |
| Forecasted Market Value ( USD | $ 360.92 Million |
| Compound Annual Growth Rate | 7.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
